Which surgery is better for advanced stomach cancer after Chemo-Immunotherapy?
NCT ID NCT06597227
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two types of stomach surgery (partial vs. total removal) for people with advanced upper gastric cancer who have already received chemotherapy combined with an immunotherapy drug. The goal is to see which surgery leads to better long-term outcomes, such as preventing cancer from coming back. About 404 participants will be randomly assigned to one of the two surgeries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ipilimumab + Sintilimab + XELOX for Gastric Canc NCT07638631
- Beta-blockers & Gastric Cancer: NCT07622693
- HIPEC + Immunotherapy for Gastric Cancer Trial NCT07621484
- PULSAR + Immunotherapy for Gastric Cancer (NCT07607119)
- AI Predicts Gastric Cancer Treatment Response (NCT07401199)
- Serplulimab Combo for Stomach Cancer Trial (NCT06576921)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••